phentolamine mesylate

Trade name: regitine

Small moleculeapproved

Approved

Jan 30, 1952

Phentolamine (trade name Regitine) is a reversible nonselective α-adrenergic antagonist used for the control of hypertensive emergencies, most notably due to pheochromocytoma. Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors (primarily excitatory responses of smooth muscle and exocrine glands), leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. The action of phentolamine on the alpha-adrenergic receptors is relatively transient and the blocking effect is incomplete. The drug is more effective in antagonizing responses to circulating epinephrine and/or norepinephrine than in antagonizing responses to mediator released at the adrenergic nerve ending. Phentolamine also stimulates β-adrenergic receptors and produces a positive inotropic and chronotropic effect on the heart and increases cardiac output. Phentolamine is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine is also indicated for the diagnosis of pheochromocytoma by the Phentolamine blocking test. Acute and prolonged hypotensive episodes, tachycardia, and cardiac arrhythmias have been reported. In addition, weakness, dizziness, flushing, orthostatic hypotension, nasal stuffiness, nausea, vomiting, and diarrhea may occur. — NCATS

Clinical trial activity

44 trials · 55 clinical orgs · 6 marketing orgs

Phase 1
6
Phase 2
22
Phase 3
15
Phase 4
3

Earliest trial started Aug 1, 2001 (NCT00080808)

Timeline

1950s

  1. Jan 30, 1952

    Novartis — Earliest FDA Approval

  2. Jan 30, 1952

    Novartis — NDA Secondary Org

  3. Jan 30, 1952

    Novartis — NDA Organization

1990s

  1. Mar 11, 1998

    West-Ward Pharmaceutical — Marketing Organization

  2. Mar 11, 1998

    Hikma — Marketing Organization

2000s

  1. Jan 1, 2001

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  4. May 9, 2008

    Septodont — NDA Secondary Org

  5. May 9, 2008

    Deproco — NDA Secondary Org

2010s

  1. Jul 14, 2017

    Precision Dose — Marketing Organization

Indications

Mechanism of action

Approval history

  • approvedPriority reviewJan 30, 1952

Chemistry & pharmacology

Loading structure…

SMILES

Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
Mol. weight
281.36 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral, Topical
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

Yes

Sources

Also known as

  • 2-(n-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
  • 2-(n-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline
  • fentolamina
  • fentolamina
  • fentolamine
  • oraverse
  • oraverse
  • oraverse
  • phentholamine
  • phentolamin
  • phentolamin
  • phentolamine
  • phentolamine
  • phentolamine
  • phentolamine
  • phentolamine
  • phentolamine
  • phentolamine
  • phentolamine
  • phentolamine
  • phentolamine
  • phentolamine hcl
  • phentolamine hydrochloride
  • phentolamine mesilate
  • phentolamine mesilate
  • phentolamine mesilate
  • phentolamine mesylate
  • phentolamine mesylate
  • phentolamine mesylate
  • phentolamine mesylate
  • phentolamine mesylate
  • phentolamine mesylate
  • phentolamine methanesulfonate
  • phentolamine methanesulfonate
  • phentolaminum
  • phentolaminum
  • regitina
  • regitina
  • regitine
  • regitine
  • regitine
  • rogitine
  • rogitine
  • trimix
  • trimix
  • vesomax
  • vesomax

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07140783Phase 3Sep 2, 2025Ocuphire Pharma, Inc.
NCT07012512N/AJun 1, 2025Mansoura University
NCT06620991N/AOct 10, 2024Ain Shams University
NCT06422494N/ASep 30, 2024Radboud University
NCT06542497Phase 3Aug 15, 2024Ocuphire Pharma, Inc.
NCT06385600N/AMay 20, 2024Assiut University
NCT06349759Phase 3Apr 1, 2024Ocuphire Pharma, Inc., Viatris
NCT06286059Phase 2/Phase 3 (Phase 3)Mar 7, 2024Helwan University
NCT05687669Phase 4Jan 12, 2023Assiut University
NCT05646719Phase 3Dec 12, 2022Ocuphire Pharma, Inc.
NCT05448807Phase 3Oct 31, 2022Cairo University
NCT05525416N/AJul 28, 2022University of Alberta
NCT05223478Phase 3Dec 17, 2021Ocuphire Pharma, Inc.
NCT05473858Phase 3Dec 10, 2021Al Azhar University
NCT05134974Phase 3Nov 18, 2021Ocuphire Pharma, Inc.
NCT04675151Phase 2Jan 31, 2021Ocuphire Pharma, Inc.
NCT04638660Phase 3Dec 30, 2020Ocuphire Pharma, Inc.
NCT04620213Phase 3Nov 18, 2020Ocuphire Pharma, Inc.
NCT04436731Early Phase 1 (Phase 1)Jul 1, 2020University of Missouri
NCT04024891Phase 2Jul 31, 2019Ocuphire Pharma, Inc.
Showing 20 of 44 trials
Page 1 / 3

Organizations

Research & Development (55)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Ocuphire Pharma, Inc.For profit121222007
Novalar Pharmaceuticals, Inc.For profit4422003
Free University of BrusselsAcademic/Hospital3122009
Assiut UniversityAcademic/Hospital2222023
Dalhousie UniversityAcademic/Hospital2222015
eTheRNAFor profit2022017
National Health and Medical Research Council, AustraliaGovernment2022005
Radboud UniversityAcademic/Hospital2212005
Tufts UniversityAcademic/Hospital2012006
University of BarcelonaAcademic/Hospital2122015
University of New South WalesAcademic/Hospital2222005
University of PennsylvaniaAcademic/Hospital2122012
Ain Shams UniversityAcademic/Hospital1112024
Al Azhar UniversityAcademic/Hospital1112021
AsphalionFor profit1012017
Badalona Hospital Germans Trias i PujolAcademic/Hospital1012017
Benha UniversityAcademic/Hospital1112019
Cairo UniversityAcademic/Hospital1112022
Conselho Nacional de Desenvolvimento Científico e TecnológicoGovernment1012012
Cornell UniversityAcademic/Hospital1112009
55 organizations
Page 1 / 3

Marketing (7)

OrganizationOrg typeRelationshipDate
DeprocoFor profitNDA2May 9, 2008
HikmaFor profitMKTGMar 11, 1998
NovartisFor profitNDA2Jan 30, 1952
NovartisFor profitNDAJan 30, 1952
Precision DoseFor profitMKTGJul 14, 2017
SeptodontFor profitNDA2May 9, 2008
West-Ward PharmaceuticalFor profitMKTGMar 11, 1998